This follow-up report is submitted to fda in accord with applicable regulations ¿ and as indicated by terumo cardiovascular systems in the initial report submitted to the fda on december 5, 2019.Upon further investigation of the reported event, the following information is new and/or changed: d1 (added brand name) d4 (additional device information - added model number and exp date) g4 (date received by manufacturer) g7 (indication that this is a follow-up report) h2 (follow-up due to additional information and device evaluation) h3 (device evaluated by manufacturer) h4 (device manufacture date) h6 (identification of evaluation codes 10, 3331, 213, 67).Method code #1: 10 - testing of actual/suspected device method code #2: 3331- analysis of production records results code: 213 - no device problem found conclusions code: 67 - no problem detected.The actual sample was returned for evaluation.Visual inspection upon receipt did not find any obvious anomaly such as break that could lead to the leakage.The blood channel after having been rinsed was filled with saline solution, then a pressure was applied.No leaks were observed.The investigation result verified that the actual sample after having been rinsed was the normal product with no issue related to the leakage.Root cause could not be determined.All available information has been placed on file in quality management for appropriate tracking, trending, and follow-up.
|